Orthofix Medical Inc Revenue per Employee (OFIX), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Orthofix Medical Inc   (NASDAQ: OFIX)
 

Orthofix Medical Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 1.51% in the first quarter 2026, year on year to cumulative value of $825 million, Orthofix Medical Inc 's revenue per employee grew on a trailing twelve months basis to $ 513,984, this marks a new company high.
Within the Healthcare sector Employees of 145 other companies have achieved higher revenue per employee. While Orthofix Medical Inc 's total ranking has deteriorated compared to the previous quarter from 588 to 1283. Orthofix Medical Inc has 1,605 employees.


What is Sales per Employee Ratio?







OFIX Revenue per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Revenue Change 1.51 % 1.61 % 4.83 % 2.42 % 2.86 %
Sales per Employee (TTM) $ 513,984 512,160 509,979 504,079 501,098
OFIX's Total Ranking # 1283 # 588 # 536 # 998 # 559
Seq. Revenue Change -10.8 % 7.21 % 1.48 % 4.6 % -10.71 %


Revenue per Employee Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 28
Healthcare Sector # 146
Overall Market # 1283

Revenue per Employee Statistics
High Average Low
$ 513,984 $ 317,850 $ 244,233
(Mar 31 2026)   (June 30. 2015)



Financial Statements
Orthofix Medical Inc 's Revenue MRQ $ 197 Millions Visit OFIX's Income Statement
Orthofix Medical Inc 's Revenues TTM $ 825 Millions Visit OFIX's aggregate revenue growth
What are OFIX's Sales? Visit OFIX's Sales by Segment


  News about Orthofix Medical Inc Revenue per employee

Orthofix Medical Inc. Appoints Massimo Calafiore as New President and CEO, Achieves Record Revenue Growth


Orthofix Medical Inc., a leading global spine and orthopedics company, has announced that Massimo Calafiore will be joining the company as its new President and Chief Executive Officer. Currently serving as the CEO of LimaCorporate S.p.A., a global orthopedics company, Calafiore is expected to assume his new role at Orthofix in early 2024, following the completion of LimaCorporate s acquisition by Enovis Corporation.
In the third quarter of 2023, Orthofix Medical Inc. saw remarkable growth, with a revenue increase of 61.2% year on year, reaching a cumulative value of $668 million, marking a new company high. Furthermore, Orthofix s revenue per employee grew on a trailing twelve months basis to $667,747.




Other Ratios
Orthofix Medical Inc 's Income per Employee
Employees in Medical Equipment & Supplies
Medical Equipment & Supplies Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
OFIX's Revenue per Employee versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for OFIX's Competitors
Revenue per Employee for OFIX's Suppliers
Revenue per Employee for OFIX's Customers

You may also want to know
OFIX's Sales Growth Rates OFIX's Pe Price to earnings ratio OFIX's Receivables Turnover Ratio OFIX's Stock Quote
OFIX's Net Income Growth Rates OFIX's Ps Price to Sales ratio OFIX's Sales per Employee OFIX's Asset Turnover Ratio
OFIX's Net Margin OFIX's Pb Price to Book ratio OFIX's Financial Strength Ratios OFIX's Dividend Payout Ratio
Date modified: 2026-08-30T14:42:49+00:00




Companies with similar Revenue per Employee for 12 months ending Mar 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Mar 31 2026Number of Employees Mar 31 2026
Pacira Biosciences inc   886,446.32 $ 734.864  Million 829 
Keenova Therapeutics Plc  883,125.00 $ 1,413.000  Million 1,600 
Nektar Therapeutics  883,063.49 $ 55.633  Million 63 
Merck and Co Inc   876,906.67 $ 65,768.000  Million 75,000 
Arrowhead Pharmaceuticals Inc   874,836.85 $ 622.009  Million 711 
Ardelyx inc   874,599.18 $ 427.679  Million 489 
Lifevantage Corp  868,242.15 $ 193.618  Million 223 
Prothena Corporation Public Limited Company  864,776.12 $ 57.940  Million 67 
Alphatec Holdings Inc   861,301.20 $ 786.368  Million 913 
Lexicon Pharmaceuticals Inc   859,790.12 $ 69.643  Million 81 
The Oncology Institute Inc   851,425.90 $ 545.764  Million 641 
Fortress Biotech Inc   848,217.95 $ 66.161  Million 78 
Pfizer Inc  844,200.00 $ 63,315.000  Million 75,000 
Carlisle Companies Incorporated  843,423.73 $ 4,976.200  Million 5,900 
Ptc Therapeutics inc   834,621.59 $ 827.110  Million 991 
Sanuwave Health Inc   805,963.64 $ 44.328  Million 55 
Xtant Medical Holdings Inc   801,331.13 $ 121.001  Million 151 
Novavax inc   796,178.91 $ 596.338  Million 749 
Marker Therapeutics inc   789,851.20 $ 3.949  Million
Immunocore Holdings Plc  787,809.16 $ 412.812  Million 524 
Adma Biologics Inc   784,800.62 $ 507.766  Million 647 
Axsome Therapeutics Inc   765,660.54 $ 708.236  Million 925 
Alkermes Plc   762,097.56 $ 1,562.300  Million 2,050 
Dyadic International Inc   761,545.80 $ 3.808  Million
Geron Corporation  759,135.66 $ 195.857  Million 258 
Emergent Biosolutions Inc   752,000.00 $ 676.800  Million 900 
Cerus Corporation  749,159.72 $ 215.758  Million 288 
Ionis Pharmaceuticals Inc   736,863.05 $ 1,033.082  Million 1,402 
Vericel Corporation  733,884.42 $ 292.086  Million 398 
Syndax Pharmaceuticals Inc   728,771.81 $ 217.174  Million 298 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.